Dr. Bayrhoffer, a physician by training, is a successful executive with a background in clinical development, strategy consulting, and financial advisory. After starting his career at The Boston Consulting Group, Dr. Bayrhoffer attained global leadership positions with life-science companies in Europe, US, India, and Latin America. As an accomplished entrepreneur, he has successfully advanced innovative technologies in the life sciences from concept to product launch. He holds several non-executive positions in pharmaceutical and life-science companies. In 2022 Dr Bayrhoffer was appointed Co-Opted Member of the Access to Medicines Task Force of the International League Against Epilepsy (ILAE).

Dr. Schefter boasts a long and successful career in the global pharmaceutical industry. An economist by training he started his career at Bayer AG in Germany. After holding multiple positions within the Bayer group, including Head of Sales & Marketing for North America and Latin America, he became CEO of Intendis Inc., the dermatology business of Bayer. During his tenure at Intendis, he managed over 2,000 employees and launched many successful dermatology products world-wide. Dr. Schefter is a frequent advisor on dermatology related topics to investors in Life Sciences, including leading Private Equity groups in the US and Europe.

Mr. Braithwaite has close to 20 years expertise in cross-cultural partnership management, sales, marketing, BD, and operations. Through multiple international positions, he built up an understanding of international business dynamics of the pharmaceutical industry and sensitivity to local cultural differences. Following a 10 year-long career at Almirall, where he became Area Manager for Asia Pacific and Chief Representative of Almirall China, Mr. Braithwaite founded Luqa Pharmaceutical in 2010. Luqa was a China-based specialty pharmaceutical company dedicated to innovative dermatology and aesthetics products. Following a success story of continued growth, Luqa was sold to one of the largest Chinese dermatology companies, CMS Aesthetics, in 2021. Since then, Mr. Braithwaite has assumed executive and non-executive positions in several global aesthetics companies.

Mr Goodman has held positions of increasing responsibilities at pharmaceutical companies and Contract Research Organizations in the US and Europe. During his career he help positions such as Director, Marketing for Purdue Pharma, and Director, Business Development for PRA International, now ICON, a global CRO. From 2005 through 2017 he assumed roles of increasing responsibilities at Reckitt Benckiser Pharmaceuticals, which was later demerged from the parent group as Indivior PLC (UK), until being appointed to Chief Business Development Officer of Indivior PLC, overseeing all business operations of a $1.5B revenue entity.  As CBO, he served as Member of the Executive Committee responsible for taking Reckitt Benckiser Pharmaceuticals public on the London Exchange (INDV). Since then, he has served as non-executive board member on multiple private and public companies, and he is an expert in compliance and compensation and member of the National Association of Corporate Directors, US.